---
title: "SHENGDA BIO-PHARM expects to turn a profit, with a projected net profit of 26 million to 36 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225528824.md"
description: "SHENGDA BIO-PHARM expects a net profit of 26 million to 36 million yuan in 2024, achieving a turnaround from losses to profits. The company aims to reduce costs and improve efficiency through refined management and technological upgrades, while deepening its differentiated competition strategy, focusing on the pharmaceutical-grade vitamin market, optimizing product sales structure, and promoting revenue growth of high-value products"
datetime: "2025-01-20T09:13:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225528824.md)
  - [en](https://longbridge.com/en/news/225528824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225528824.md)
---

# SHENGDA BIO-PHARM expects to turn a profit, with a projected net profit of 26 million to 36 million yuan in 2024

According to the announcement from Shengda Bio-Pharm (603079.SH), the company expects to achieve a net profit attributable to the owners of the parent company of between 26 million yuan and 36 million yuan for the year 2024, marking a turnaround from a loss compared to the same period last year (statutory disclosure data).

During the reporting period, the company focused on refined management and technological improvements, achieving cost reduction and efficiency enhancement. At the same time, the company deepened its differentiated competition strategy, intensifying its market development efforts for pharmaceutical-grade vitamins and clean label products, resulting in an optimized sales structure compared to the same period last year. During the reporting period, the operating income of the company's pharmaceutical-grade vitamin products and clean label products, among other high-value products, increased year-on-year

### Related Stocks

- [603079.CN](https://longbridge.com/en/quote/603079.CN.md)
- [300401.CN](https://longbridge.com/en/quote/300401.CN.md)
- [600056.CN](https://longbridge.com/en/quote/600056.CN.md)
- [600420.CN](https://longbridge.com/en/quote/600420.CN.md)
- [002727.CN](https://longbridge.com/en/quote/002727.CN.md)
- [301096.CN](https://longbridge.com/en/quote/301096.CN.md)
- [002728.CN](https://longbridge.com/en/quote/002728.CN.md)
- [002826.CN](https://longbridge.com/en/quote/002826.CN.md)
- [003020.CN](https://longbridge.com/en/quote/003020.CN.md)
- [600721.CN](https://longbridge.com/en/quote/600721.CN.md)
- [600998.CN](https://longbridge.com/en/quote/600998.CN.md)
- [603235.CN](https://longbridge.com/en/quote/603235.CN.md)
- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)
- [002001.CN](https://longbridge.com/en/quote/002001.CN.md)

## Related News & Research

- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [Baseball-MLB owners unanimously approve sale of San Diego Padres](https://longbridge.com/en/news/296137237.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [HELP Therapeutics Announces Nature Medicine Has Published HiCM-188 Clinical Trial Data for Advanced Ischemic Heart Failure](https://longbridge.com/en/news/296448083.md)